Cargando…
Photoinduced Conversion of Antimelanoma Agent Dabrafenib to a Novel Fluorescent BRAF(V600E) Inhibitor
[Image: see text] Dabrafenib (Tafinlar) was approved in 2013 by the FDA as a selective single agent treatment for patients with BRAF(V600E) mutation-positive advanced melanoma. One year later, a combination of dabrafenib and trametinib was used for treatment of BRAF(V600E/K) mutant metastatic melano...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical
Society
2016
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066145/ https://www.ncbi.nlm.nih.gov/pubmed/27774137 http://dx.doi.org/10.1021/acsmedchemlett.6b00340 |